RTW Investments LP Purchases Shares of 150,289 Bellicum Pharmaceuticals Inc (BLCM)

RTW Investments LP purchased a new stake in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 150,289 shares of the biopharmaceutical company’s stock, valued at approximately $1,109,000. RTW Investments LP owned about 0.35% of Bellicum Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its position in shares of Bellicum Pharmaceuticals by 52.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 6,530 shares during the last quarter. Knott David M lifted its position in shares of Bellicum Pharmaceuticals by 12.8% during the 1st quarter. Knott David M now owns 67,653 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 7,669 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Bellicum Pharmaceuticals by 161.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 10,466 shares during the last quarter. Swiss National Bank lifted its position in shares of Bellicum Pharmaceuticals by 32.3% during the 2nd quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 14,300 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Bellicum Pharmaceuticals by 21.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,524 shares of the biopharmaceutical company’s stock valued at $844,000 after buying an additional 22,335 shares during the last quarter. 59.31% of the stock is currently owned by hedge funds and other institutional investors.

BLCM has been the topic of a number of analyst reports. BidaskClub lowered Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Cantor Fitzgerald set a $18.00 price objective on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 7th. ValuEngine lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 21st. Finally, Citigroup decreased their price objective on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $14.48.

NASDAQ:BLCM opened at $6.26 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.24 and a current ratio of 10.24. Bellicum Pharmaceuticals Inc has a 52-week low of $5.02 and a 52-week high of $13.30. The firm has a market cap of $302.58 million, a P/E ratio of -2.20 and a beta of 0.54.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.05). The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.08 million. research analysts forecast that Bellicum Pharmaceuticals Inc will post -2.37 earnings per share for the current year.

In other Bellicum Pharmaceuticals news, insider David M. Spencer sold 40,000 shares of the company’s stock in a transaction dated Wednesday, July 18th. The stock was sold at an average price of $7.63, for a total value of $305,200.00. Following the transaction, the insider now directly owns 99,939 shares in the company, valued at approximately $762,534.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO David M. Spencer sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $7.04, for a total value of $70,400.00. Following the completion of the transaction, the chief technology officer now owns 89,939 shares in the company, valued at $633,170.56. The disclosure for this sale can be found here. 9.84% of the stock is owned by corporate insiders.

Bellicum Pharmaceuticals Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Recommended Story: Asset Allocation, Balancing Your Investments

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply